IL18 and neoplasm: Although there is scant evidence to suggest that the mechanism of tumor inhibition is related to induction of pyroptosis in previously normal cells undergoing transformation to tumor cells, release of IL-1β and IL-18 can lead to infiltration and activation of immune cells at tumor sites, thereby supporting the anti-tumor immune response (61).